| Literature DB >> 22607610 |
Wang Deng1, Min Yu, Hilary Ma, Liang An Hu, Gang Chen, Yong Wang, Jia Deng, ChangYi Li, Jin Tong, Dao Xin Wang.
Abstract
BACKGROUND: Miliary tuberculosis (TB) is an uncommon cause of acute respiratory distress syndrome (ARDS) with a high mortality. The aim of the present study was to evaluate the clinical characteristics, predictors and outcome of patients with ARDS caused by miliary TB.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22607610 PMCID: PMC3407496 DOI: 10.1186/1471-2334-12-121
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical characteristics, investigations and outcome of patients with ARDS caused by miliary TB (n = 85)
| Parameters | Results |
|---|---|
| Age (years) | 36.6 ± 12.5 |
| Sex (male) | 38(44.7%) |
| Clinical findings | |
| Fever, cough, dyspnoea, weight loss | 85 (100) |
| Diabetes mellitus | 16 (18.8) |
| Past history of tuberculosis | 9(10.6) |
| Hepatitis B | 8 (9.4) |
| Pregnancy | 3 (3.5) |
| Heart disease | 3(3.5) |
| Cerebrovascular disease | 2(2.3) |
| Investigations | |
| APACHE III score | 71.6 ± 21.9 |
| PaO2/FiO2(mmHg) | 146.4 ± 34.5 |
| Outcome | |
| Duration of symptoms (days) | 16.1 ± 5.2 |
| Misdiagnosis for other diseases | 33 (38.8) |
| Time to diagnosis (days) | 7.2 ± 3.4 |
| Length of stay in the ICU(days) | 15.3 ± 3.5 |
| Length of stay in the hospital(days) | 26.7 ± 4.6 |
| Duration of mechanical ventilation (days) | 8.5 ± 3.0 |
| Time from admission to anti-tuberculosis therapy (days) | 4.5 ± 2.0 |
| Glucocorticoids therapy | 35 (41.2) |
| ICU mortality | 40(47.1) |
Data are presented as mean + SD or n(%).
Comparisons of demographic parametres, clinical and laboratory characteristics between ARDS group and non-ARDS group
| ARDS(n = 85) | non-ARDS(n = 381) | P-value | |
|---|---|---|---|
| Age(years) | 36.6 ± 12.5 | 38.1 ± 11.9 | 0.892 |
| Sex(male) | 38(44.7%) | 113(40.2%) | 0.710 |
| ALT (U/L) | 73.7 ± 20.9 | 30.9 ± 25.8 | 0.001 |
| AST (U/L) | 94.7 ± 18.2 | 35.7 ± 23.1 | 0.001 |
| ESR(mm/the first hour) | 40.3 ± 18.8 | 42.8 ± 28.6 | 0.653 |
| D-dimer (g/L) | 1.2 ± 0.5 | 0.3 ± 0.2 | 0.001 |
| Hemoglobin (g/L) | 83.5 ± 16.2 | 125.4 ± 35.4 | 0.011 |
| Albumin (g/L) | 29.3 ± 3.7 | 40.2 ± 14.1 | 0.001 |
Data are presented as mean + SD or n (%).AST: aspartate aminotransferase; ALT: alanine aminotransferase. ESR:erythrocyte sedimentation rate.
Comparisons of demographic parametres, clinical and laboratory characteristics between survivors and non-survivors of ARDS patients
| Survivors(n = 45) | Non-survivors(n = 40) | ||
|---|---|---|---|
| Age(years) | 35.8 ± 9.5 | 37.1 ± 14.2 | 0.899 |
| Sex(male) | 20(44.4) | 18(45) | 0.745 |
| DM | 4(8.89) | 12(30) | 0.017 |
| APACHE III score | 70.4 ± 23.6 | 72.8 ± 19.1 | 0.856 |
| PaO2/FiO2(mmHg) | 149.5 ± 37.8 | 143.7 ± 31.9 | 0.648 |
| Time to diagnosis (days) | 3.2 ± 2.7 | 11.8 ± 4.1 | 0.002 |
| Time from diagnosis to mechanical ventilation (days) | 2.5 ± 3.4 | 8.6 ± 5.3 | 0.034 |
| Time from admission to anti-tuberculosis therapy (days) | 2.8 ± 1.6 | 6.9 ± 3.8 | 0.046 |
| Length of stay in the ICU(days) | 19.3 ± 4.9 | 12.4 ± 3.2 | 0.267 |
| Length of stay in the hospital(days) | 29.4 ± 5.6 | 17.3 ± 4.2 | 0.366 |
| ALT (U/L) | 56.2 ± 19.6 | 93.2 ± 22.4 | 0.038 |
| AST (U/L) | 63.8 ± 18.1 | 118.2 ± 21.4 | 0.019 |
| ESR(mm/the first hour) | 40.0 ± 18.1 | 40.6 ± 18.9 | 0.714 |
| D-dimer (g/L) | 0.6 ± 0.8 | 1.8 ± 0.6 | 0.017 |
| Hemoglobin (g/L) | 92.7 ± 14.8 | 76.2 ± 20.9 | 0.032 |
| Albumin (g/L) | 34.6 ± 3.9 | 23.9 ± 3.2 | 0.027 |
Data are presented as mean ± SD or n(%).AST: aspartate aminotransferase; ALT: alanine aminotransferase; ESR:erythrocyte sedimentation rate; DM:diabetes mellitus.
The levels of predicators for ARDS development caused by military TB
| Predicators | Sensitivity | Specificity | Positive likelihood ratio |
|---|---|---|---|
| ALT | | | |
| Level1 | 41.9% | 4.8% | 0.44 |
| Level 2 | 19.4% | 96.3% | 5.24 |
| Level 3 | 25.8% | 99.7% | 86.00 |
| Level 4 | 12.9% | 99.1% | 14.33 |
| AST | | | |
| Level1 | 32.2% | 8.5% | 0.35 |
| Level 2 | 22.6% | 96.0% | 5.65 |
| Level 3 | 29.0% | 96.0% | 7.25 |
| Level 4 | 16.1% | 99.4% | 26.83 |
| D-dimer | | | |
| Level1 | 64.5% | 23.7% | 0.84 |
| Level 2 | 25.8% | 76.8% | 1.11 |
| Level 3 | 3.2% | 99.4% | 5.33 |
| Level 4 | 6.5% | 100% | +∞ |
| Hemoglobin | | | |
| Level1 | 22.6% | 8.2% | 0.25 |
| Level 2 | 19.4% | 93.5% | 2.98 |
| Level 3 | 22.6% | 98.9% | 20.55 |
| Level 4 | 35.5% | 99.4% | 59.16 |
| Albumin | | | |
| Level1 | 16.1% | 5.6% | 0.17 |
| Level 2 | 58.1% | 96.3% | 15.70 |
| Level 3 | 12.9% | 98.6% | 9.21 |
| Level 4 | 12.9% | 99.4% | 21.50 |
ALT:Level 1:0-40U/L;Level 2:40-70U/L;Level 3:70-100U/L;Level 4: > 100U/L.
AST:Level 1: < 34U/L;Level 2:34-64U/L;Level 3:64-94U/L;Level 4: > 94U/L.
D-dimer:Level 1: < 0.34mg/L;Level 2:0.34-1.0mg/L;Level 3:1.0-1.6mg/L;Level 4: > 1.6mg/L;
Hemoglobin:Level 1:110-160g/L;Level 2:100-110 g/L;Level 3:90-100 g/L;Level 4: < 90 g/L;
Albumin:Level 1:35-50 g/L;Level 2:30-35g/L;Level 3:25-30 g/L;Level 4: < 25 g/L.